Overview

  • Product nameAnti-MIF antibody
    See all MIF primary antibodies
  • Description
    Goat polyclonal to MIF
  • SpecificityRecognizes recombinant and natural human Migration Inhibitory Factor (MIF). Based on direct ELISA, shows no crossreactivity with most cytokines
  • Tested applicationsSuitable for: ELISA, WBmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    E. coli-derived recombinant full length protein (Human).

  • General notes= 10ng/mg Endotoxin.

Properties

  • FormLiquid
  • Storage instructionsShipped at 4°C. Add glycerol to a final volume of 50% for extra stability and aliquot. Store at -20°C. Avoid freeze / thaw cycle.
  • Storage bufferPreservative: None
    Constituents: PBS, pH 7.2
  • Concentration information loading...
  • PurityImmunogen affinity purified
  • Purification notesPurified by immunoaffinity chromatography.
  • ClonalityPolyclonal
  • IsotypeIgG
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab14574 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ELISA
WB
  • Application notesELISA: Use at a concentration of 0.5 - 1 µg/ml. Detection limit 0.15ng/well.
    WB: Use at a concentration of 0.1 - 0.2 µg/ml. Predicted molecular weight: 13.8 kDa. Detection limit 5ng/lane.

    Not tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionPro-inflammatory cytokine. Involved in the innate immune response to bacterial pathogens. The expression of MIF at sites of inflammation suggests a role as mediator in regulating the function of macrophages in host defense. Counteracts the anti-inflammatory activity of glucocorticoids. Has phenylpyruvate tautomerase and dopachrome tautomerase activity (in vitro), but the physiological substrate is not known. It is not clear whether the tautomerase activity has any physiological relevance, and whether it is important for cytokine activity.
    • Involvement in diseaseGenetic variations in MIF are associated with susceptibility to rheumatoid arthritis systemic juvenile (RASJ) [MIM:604302]. An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis.
    • Sequence similaritiesBelongs to the MIF family.
    • Cellular localizationSecreted. Cytoplasm. Does not have a cleavable signal sequence and is secreted via a specialized, non-classical pathway. Secreted by macrophages upon stimulation by bacterial lipopolysaccharide (LPS), or by M.tuberculosis antigens.
    • Information by UniProt
    • Database links
    • Alternative names
      • acrophage migration inhibitory factor (glycosylation-inhibiting factor) antibody
      • GIF antibody
      • GLIF antibody
      • Glycosylation inhibiting factor antibody
      • Glycosylation-inhibiting factor antibody
      • L-dopachrome isomerase antibody
      • L-dopachrome tautomerase antibody
      • Macrophage migration inhibitory factor antibody
      • MIF antibody
      • MIF protein antibody
      • MIF_HUMAN antibody
      • MMIF antibody
      • Phenylpyruvate tautomerase antibody
      see all

    References for Anti-MIF antibody (ab14574)

    ab14574 has not yet been referenced specifically in any publications.

    Product Wall

    Thank you for your enquiry. I have found reference to the use of LPS stimulated RAW cell lysate, Neuro2A (mouse neuroblastoma cell line) lysate or a Human Thymus lysate for use as a positive control for antibodies against MIF. Unfortunately we do...

    Read More

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"